Coherus Oncology, Inc.CHRSNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank51
3Y CAGR-85.1%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-85.1%/yr
vs -24.2%/yr prior
Acceleration
-60.9pp
Decelerating
Percentile
P51
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 0.12% |
| Q3 2025 | 2.53% |
| Q2 2025 | -0.11% |
| Q1 2025 | -7.55% |
| Q4 2024 | -561.44% |
| Q3 2024 | 68.86% |
| Q2 2024 | 69.74% |
| Q1 2024 | 1.62% |
| Q4 2023 | -115.29% |
| Q3 2023 | 7.34% |
| Q2 2023 | 49.01% |
| Q1 2023 | -31.56% |
| Q4 2022 | 35.99% |
| Q3 2022 | -82.78% |
| Q2 2022 | 45.61% |
| Q1 2022 | -104.63% |
| Q4 2021 | -20.62% |
| Q3 2021 | -35.69% |
| Q2 2021 | 85.56% |
| Q1 2021 | -1118.93% |
| Q4 2020 | -51.28% |
| Q3 2020 | -48.38% |
| Q2 2020 | 59.81% |
| Q1 2020 | -9.25% |
| Q4 2019 | -13.13% |
| Q3 2019 | 88.56% |
| Q2 2019 | 265.63% |
| Q1 2019 | 72.56% |
| Q4 2018 | -6.20% |
| Q3 2018 | -26.86% |
| Q2 2018 | -6.85% |
| Q1 2018 | 9.54% |
| Q4 2017 | 17.93% |
| Q3 2017 | 0.04% |
| Q2 2017 | 21.79% |
| Q1 2017 | 1.42% |
| Q4 2016 | -186.81% |
| Q3 2016 | 234.88% |
| Q2 2016 | 2.51% |
| Q1 2016 | -23.26% |